{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:18:12Z","timestamp":1790882292488,"version":"4.1.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Concomitant medications may influence the tumor\u2013immune microenvironment and potentially affect the efficacy of immune checkpoint inhibitors (ICIs), yet their impact in hepatobiliary malignancies remains poorly defined. We evaluated the associations of antibiotic (ATB) exposure and indication-specific corticosteroid (CS) use with clinical outcomes in hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective cohort of 759 ICI-treated patients (511 HCC, 248 CCA), patients were stratified into four groups: no exposure (None, n=251), ATB only (n=135), CS only (n=183), and combined exposure (Both, n=190). ATB exposure was defined as systemic use within \u00b130 days of ICI initiation, and CS exposure as \u226510 mg prednisone-equivalent daily for \u22653 consecutive days. Inverse probability of treatment weighting (IPTW) and multivariable Cox models were used to adjust for confounding. Additional baseline-only sensitivity analyses restricted exposure to the 30 days before ICI initiation to reduce potential time-related bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After IPTW adjustment, baseline covariates were well balanced across exposure groups. Combined ATB and CS exposure was associated with significantly worse overall survival (OS) (adjusted HR 3.09, 95% CI 2.31\u20134.13; p&amp;lt;0.001) and progression-free survival (PFS) compared with no exposure. Objective response rates were comparable across groups (p=0.20), suggesting a greater association with impaired response durability rather than initial tumor shrinkage. Among CS-treated patients, corticosteroid use for immune-related adverse event (irAE) management was associated with improved OS compared with non-irAE indications (p&amp;lt;0.01). Landmark and baseline-only sensitivity analyses demonstrated generally consistent findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Antibiotic exposure and corticosteroid use for non-irAE indications were associated with inferior survival outcomes in ICI-treated hepatobiliary malignancies. These findings suggest that concomitant medication exposure may influence the durability of immunotherapy responses in real-world clinical settings. In contrast, corticosteroid use for irAEs was not associated with compromised outcomes, supporting the importance of context-specific corticosteroid administration during immunotherapy. Clinically, these findings highlight the importance of judicious antibiotic use and careful consideration of corticosteroid indications during ICI treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1873839","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:38:46Z","timestamp":1782711526000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Antibiotic exposure and indication-specific corticosteroid use differentially modulate outcomes of immune checkpoint inhibitor therapy in hepatobiliary malignancies"],"prefix":"10.3389","volume":"17","author":[{"given":"Jiabao","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Radiotherapy, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Jiao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhekang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuwei","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Lan","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zirui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Xi\u2032an Jiaotong University","place":["Xi\u2032an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beina","family":"Hui","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasneem Ibrahim Dawalbait","family":"Bakhat","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2023.107313","article-title":"Hepatocellular carcinoma","volume":"50","author":"Dopazo","year":"2024","journal-title":"Eur J Surg Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2023.107064","article-title":"Epidemiology of cholangiocarcinoma","volume":"51","author":"Qurashi","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.annonc.2025.02.006","article-title":"Hepatocellular carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"36","author":"Vogel","year":"2025","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"B5","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S1470-2045(21)00151-0","article-title":"Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial","volume":"22","author":"Galle","year":"2021","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: The CheckMate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","article-title":"mRECIST for HCC: Performance and novel refinements","volume":"72","author":"Llovet","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1159\/000549355","article-title":"Rechallenge with immune checkpoint inhibitors in patients with hepatocellular carcinoma: A narrative review","author":"Li","year":"2025","journal-title":"Liver Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.2785","article-title":"Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer","volume":"5","author":"Pinato","year":"2019","journal-title":"JAMA Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2026.01.009","article-title":"Revisiting prophylactic corticosteroids to mitigate severe immune-related adverse events in hepatocellular carcinoma","volume":"84","author":"Shen","year":"2026","journal-title":"J Hepatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1680015","article-title":"Concomitant medication use and clinical outcome in hepatocellular carcinoma treated with immune-based therapy: a multicenter analysis","volume":"16","author":"Yi","year":"2025","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00191","article-title":"Corticosteroids for immune-related adverse events and checkpoint inhibitor efficacy: Analysis of six clinical trials","volume":"42","author":"Verheijden","year":"2024","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical","year":"2013","journal-title":"JAMA"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy103","article-title":"Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer","volume":"29","author":"Derosa","year":"2018","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000726","article-title":"Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy","volume":"8","author":"Pinato","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111138","article-title":"Impact of prophylactic dexamethasone on the efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy in patients with advanced non-squamous non-small-cell lung cancer","volume":"125","author":"Yu","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l5657","article-title":"Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners","volume":"367","author":"Desai","year":"2019","journal-title":"BMJ"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer","volume":"4","author":"Mezquita","year":"2018","journal-title":"JAMA Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.110.957951","article-title":"Landmark analysis at the 25-year landmark point","volume":"4","author":"Dafni","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejca.2022.11.017","article-title":"Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population","volume":"180","author":"Casadei-Gardini","year":"2023","journal-title":"Eur J Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao3290","article-title":"The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients","volume":"359","author":"Matson","year":"2018","journal-title":"Science"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1177\/0962280218776690","article-title":"Assessing the performance of the generalized propensity score for estimating the effect of quantitative or continuous exposures on survival or time-to-event outcomes","volume":"28","author":"Austin","year":"2019","journal-title":"Stat Methods Med Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-0878-z","article-title":"A defined commensal consortium elicits CD8 T cells and anti-cancer immunity","volume":"565","author":"Tanoue","year":"2019","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114172","article-title":"Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma","volume":"207","author":"Verheijden","year":"2024","journal-title":"Eur J Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05400-x","article-title":"Liver tumour immune microenvironment subtypes and neutrophil heterogeneity","volume":"612","author":"Xue","year":"2022","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.01.011","article-title":"Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy","volume":"78","author":"Liu","year":"2023","journal-title":"J Hepatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70914","article-title":"Gut microbiota and hepatocellular carcinoma: Metabolic products and immunotherapy modulation","volume":"14","author":"Xiao","year":"2025","journal-title":"Cancer Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2025.2486519","article-title":"Gut microbiota in hepatocellular carcinoma immunotherapy: immune microenvironment remodeling and gut microbiota modification","volume":"17","author":"Huang","year":"2025","journal-title":"Gut Microbes"},{"key":"B37","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41571-023-00785-8","article-title":"Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy","volume":"20","author":"Thomas","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0281459","article-title":"Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma","volume":"18","author":"Maesaka","year":"2023","journal-title":"PloS One"},{"key":"B39","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1186\/s12885-021-08153-4","article-title":"Prognostic value of inflammation-based indices in patients with resected hepatocellular carcinoma","volume":"21","author":"Kong","year":"2021","journal-title":"BMC Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003334","article-title":"Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers","volume":"9","author":"Mao","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41467-021-20935-9","article-title":"Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors","volume":"12","author":"Valero","year":"2021","journal-title":"Nat Commun"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22136975","article-title":"The role of microbiota in primary sclerosing cholangitis and related biliary Malignancies","volume":"22","author":"Ozdirik","year":"2021","journal-title":"Int J Mol Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1873839\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:38:47Z","timestamp":1782711527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1873839\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":43,"alternative-id":["10.3389\/fimmu.2026.1873839"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1873839","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"article-number":"1873839"}}